Welcome to our dedicated page for AtaiBeckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
AtaiBeckley Inc. (ATAI) completed a merger in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged into AtaiBeckley on September 11, 2026, making AtaiBeckley a wholly owned subsidiary of Eli Lilly. Director Andrea Heslin Smiley reported dispositions to the issuer of multiple stock option awards and 4,666 shares of common stock. At the effective time of the merger, each common share converted into the right to receive $6.75 in cash per share plus one contingent value right (CVR) per share, and each outstanding company stock option was cancelled and converted into cash based on the excess of $6.75 over the option’s exercise price per share plus one CVR for each underlying share.
AtaiBeckley Inc. (ATAI) director Scott Braunstein reported the disposition of four stock option grants in connection with the closing of a merger in which AtaiBeckley became a wholly owned subsidiary of Eli Lilly and Company. On September 11, 2026, at the merger’s Effective Time, each covered option was automatically cancelled and converted into the right to receive cash plus a contingent value right.
The cash portion for each option equals the number of underlying common shares multiplied by the excess of $6.75 over the option’s exercise price per share, less applicable tax withholdings, and holders also receive one contingent value right (CVR) per share that can pay up to $2.50 in cash upon achievement of specified clinical and regulatory milestones. No Rule 10b5-1 trading plan is reported for these transactions.
AtaiBeckley Inc. (ATAI) completed a merger in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged into AtaiBeckley on September 11, 2026, making AtaiBeckley a wholly owned subsidiary of Eli Lilly. Co-founder, chief executive officer and director Rao Srinivas reported dispositions of common stock, options and RSUs to the issuer at the merger’s effective time, as all such equity awards were automatically cancelled and converted into rights to receive $6.75 in cash per share plus one contingent value right (CVR) per share or per underlying share, with each CVR representing up to an additional $2.50 in cash upon achievement of specified clinical and regulatory milestones. No Rule 10b5-1 trading plan is reported.
AtaiBeckley Inc. (ATAI) director Robert Hershberg reported issuer dispositions of several stock option awards on September 11, 2026, in connection with the completion of the company’s merger with a subsidiary of Eli Lilly and Company. At the merger’s effective time, these options were cancelled and converted into cash and contingent value rights.
Each cancelled option became the right to receive cash based on the $6.75 per-share merger price above its exercise price, plus one contingent value right per underlying share, which may pay up to an additional $2.50 in cash upon specified clinical and regulatory milestones.
AtaiBeckley Inc. (ATAI) director Sabrina Martucci Johnson reported the disposition of several stock option awards on September 11, 2026, in connection with the merger of AtaiBeckley with a subsidiary of Eli Lilly and Company. At the merger’s Effective Time, each reported option was cancelled and converted into cash plus one contingent value right (CVR) per underlying common share, based on a cash price of $6.75 per share minus the applicable exercise price and potential additional CVR payments of up to $2.50 per share upon specified clinical and regulatory milestones. No Rule 10b5-1 trading plan is reported for these transactions.
AtaiBeckley Inc. (ATAI) reports that, in connection with its merger into a wholly owned subsidiary of Eli Lilly and Company on September 11, 2026, all common shares and stock options reported by director and ten percent owner Christian Angermayer and related Apeiron entities were disposed of and now show zero ATAI common stock holdings.
Each share of common stock converted into the right to receive $6.75 in cash plus one contingent value right (CVR) per share, and each outstanding stock option was cancelled and converted into cash based on $6.75 minus the option’s exercise price per underlying share plus one CVR per underlying share. No Rule 10b5-1 trading plan is reported.
AtaiBeckley Inc. (ATAI) is filing post-effective amendments to two Form S-8 registration statements to deregister all remaining unsold shares of its common stock previously registered under its 2021 Incentive Award Plan and 2020 Employee, Director and Consultant Equity Incentive Plan.
On September 11, 2026, Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged with and into AtaiBeckley Inc., with AtaiBeckley continuing as the surviving corporation and becoming a wholly owned subsidiary of Eli Lilly. As a result, AtaiBeckley has terminated all offerings under these employee equity plans and is formally removing any unissued securities from registration, so that no securities remain registered under the referenced Form S-8 statements.
AtaiBeckley Inc. (ATAI) is having its common stock removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934, as reflected in a Form 25 filed for Commission File Number 001-4303.
Nasdaq states that it has complied with its rules to strike this class of securities from listing and/or withdraw registration, and AtaiBeckley Inc. is stated to have complied with the Exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing voluntary withdrawal. The notification is signed on behalf of Nasdaq Stock Market LLC by CDO Analyst Katelin Rowe.
AtaiBeckley Inc. (ATAI) is filing post-effective amendments to two Form S-8 registration statements to deregister all remaining shares of its common stock that were registered for issuance under its 2021 Incentive Award Plan and 2020 Employee, Director and Consultant Equity Incentive Plan.
The amendments follow the completion of a merger on September 11, 2026, in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged with and into AtaiBeckley Inc., leaving AtaiBeckley as the surviving corporation and a wholly owned subsidiary of Eli Lilly. As a result, all offerings and sales under the S-8 registration statements have been terminated, and after these amendments there will be no remaining securities registered under those statements.
AtaiBeckley Inc. (ATAI) filed a post-effective amendment to its Form S-3 registration statement to terminate its effectiveness and deregister all securities that were registered but unsold or unissued under that shelf. This action follows the completion of a merger in which Albali Acquisition Corporation, an indirect wholly owned subsidiary of Eli Lilly and Company, merged with and into AtaiBeckley on September 11, 2026. AtaiBeckley continues as the surviving corporation and is now a wholly owned subsidiary of Eli Lilly, and all offerings under the S-3 have been terminated.